Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

T-cell-based therapies have improved outcomes in hematologic cancers, with multiple CAR-T and BiTE approvals. However, their application in solid tumors has been limited. Recently, four novel T-cell therapies received FDA approval for solid malignancies. Research is exploring CAR-T targets like HER2, PSCA, EGFR, and GD2 in solid tumors. Addressing toxicity, manufacturing, tumor microenvironment, and neoantigen discovery are crucial for expanding these therapies to solid cancers.